Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 1 |
Cutaneous malignant melanoma | D000096142 | — | — | 1 | 1 | — | — | — | 1 |
Uterine cervical neoplasms | D002583 | — | — | — | 1 | — | — | — | 1 |
Drug common name | UPROSERTIB |
INN | uprosertib |
Description | Uprosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-alpha serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-gamma serine/threonine-protein kinase. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl |
PDB | — |
CAS-ID | 1047634-65-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3137336 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | ZXM835LQ5E (ChemIDplus, GSRS) |